Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
- 7 February 2006
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Immunology
- Vol. 18 (2), 220-225
- https://doi.org/10.1016/j.coi.2006.01.002
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppressionBlood, 2005
- A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturationBlood, 2005
- A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligationInternational Immunology, 2005
- Indolamine 2,3‐dioxygenase is expressed in the CNS and down‐regulates autoimmune inflammationThe FASEB Journal, 2005
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapyTrends in Immunology, 2005
- Expression of Indoleamine 2,3-Dioxygenase in Dermal Fibroblasts Functions as a Local Immunosuppressive FactorJournal of Investigative Dermatology, 2004
- Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-DioxygenaseScience, 2002
- Enhancement of Innate Immunity againstMycobacterium aviumInfection by Immunostimulatory DNA Is Mediated by Indoleamine 2,3-DioxygenaseInfection and Immunity, 2001
- Immunology at the Maternal-Fetal Interface: Lessons for T Cell Tolerance and SuppressionAnnual Review of Immunology, 2000